Company news

Revelation Biosciences, Inc. news in 2026

Revelation Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

November 5, 2026

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

October 16, 2026

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

August 19, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

August 6, 2026

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

August 3, 2026

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 21, 2026

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

June 1, 2026

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 11, 2026

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

April 6, 2026

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 24, 2026

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 19, 2026

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 26, 2026

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

January 26, 2026

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

January 23, 2026

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

January 21, 2026

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

January 14, 2026

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

January 7, 2026

Decks in 2026